210 related articles for article (PubMed ID: 29469204)
41. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study.
Valayannopoulos V; Baruteau J; Delgado MB; Cano A; Couce ML; Del Toro M; Donati MA; Garcia-Cazorla A; Gil-Ortega D; Gomez-de Quero P; Guffon N; Hofstede FC; Kalkan-Ucar S; Coker M; Lama-More R; Martinez-Pardo Casanova M; Molina A; Pichard S; Papadia F; Rosello P; Plisson C; Le Mouhaer J; Chakrapani A
Orphanet J Rare Dis; 2016 Mar; 11():32. PubMed ID: 27030250
[TBL] [Abstract][Full Text] [Related]
42. [The antitumor activity of L-asparaginase].
Adamson RH; Fabro S
Acta Vitaminol Enzymol; 1969; 23(3):111-24. PubMed ID: 4897937
[No Abstract] [Full Text] [Related]
43. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase.
Liebman HA; Wada JK; Patch MJ; McGehee W
Cancer; 1982 Aug; 50(3):451-6. PubMed ID: 7046902
[TBL] [Abstract][Full Text] [Related]
44. [Clinical significance of L-asparaginase].
Benkö S
Orv Hetil; 1969 Aug; 110(35):2019-23. PubMed ID: 4900161
[No Abstract] [Full Text] [Related]
45. Hyperglycemia and acute parotitis related to L-asparaginase therapy.
Uysal K; Uguz A; Olgun N; Sarialioglu F; Büyükgebiz A
J Pediatr Endocrinol Metab; 1996; 9(6):627-9. PubMed ID: 9004180
[TBL] [Abstract][Full Text] [Related]
46. Asparaginase and MOPP treatment of dogs with lymphoma.
Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
[TBL] [Abstract][Full Text] [Related]
47. L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient report.
Misgar RA; Laway BA; Rahaman SH; Wani AI; Bashir MI; Bhat JR
J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):439-41. PubMed ID: 25210761
[TBL] [Abstract][Full Text] [Related]
48. [L-asparaginase and leukemia].
Grundmann E
Klin Wochenschr; 1969 Jan; 47(2):61-4. PubMed ID: 4904781
[No Abstract] [Full Text] [Related]
49. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
50. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Buie LW; Moore J; van Deventer H
Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
[TBL] [Abstract][Full Text] [Related]
51. L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha.
Panigrahi M; Swain TR; Jena RK; Panigrahi A
Indian J Pharmacol; 2016; 48(5):595-598. PubMed ID: 27721550
[TBL] [Abstract][Full Text] [Related]
52. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
53. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
[TBL] [Abstract][Full Text] [Related]
54. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
55. Preclinical evaluation of L-asparaginase and methotrexate administered at intermediate doses in dogs.
Bortnowski HB; Rosenthal RC
Am J Vet Res; 1991 Oct; 52(10):1636-8. PubMed ID: 1767984
[TBL] [Abstract][Full Text] [Related]
56. [L-asparaginase--first specific cytostatic].
Marquardt H
Arzneimittelforschung; 1968 Nov; 18(11):1380-6. PubMed ID: 4885156
[No Abstract] [Full Text] [Related]
57. L-asparaginase--clinical experience in leukaemia, lymphoma and carcinoma.
Biggs JC; Chesterman CN; Holliday J
Aust N Z J Med; 1971 Feb; 1(1):1-7. PubMed ID: 4934741
[No Abstract] [Full Text] [Related]
58. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
[TBL] [Abstract][Full Text] [Related]
59. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
[TBL] [Abstract][Full Text] [Related]
60. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.
Cheung NK; Chau IY; Coccia PF
Am J Pediatr Hematol Oncol; 1986; 8(2):99-104. PubMed ID: 3526939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
